Premium
Preventive HIV Vaccine Acceptability and Behavioral Risk Compensation among a Random Sample of High‐Risk Adults in Los Angeles (LA VOICES)
Author(s) -
Newman Peter A.,
Lee SungJae,
Duan Naihua,
Rudy Ellen,
Nakazono Terry K.,
Boscardin John,
Kakinami Lisa,
Shoptaw Steven,
Diamant Allison,
Cunningham William E.
Publication year - 2009
Publication title -
health services research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.706
H-Index - 121
eISSN - 1475-6773
pISSN - 0017-9124
DOI - 10.1111/j.1475-6773.2009.01039.x
Subject(s) - medicine , psychological intervention , vaccination , condom , demography , risk perception , environmental health , family medicine , gerontology , human immunodeficiency virus (hiv) , psychology , nursing , immunology , syphilis , neuroscience , sociology , perception
Objective. To assess HIV vaccine acceptability among high‐risk adults in Los Angeles. Study Setting. Sexually transmitted disease clinics, needle/syringe exchange programs, Latino community health/HIV prevention programs. Study Design. Cross‐sectional survey using conjoint analysis. Participants were randomly selected using three‐stage probability sampling. Data Collection. Sixty‐minute structured interviews. Participants rated acceptability of eight hypothetical vaccines, each with seven dichotomous attributes, and reported post‐vaccination risk behavior intentions. Principal Findings. Participants ( n =1164; 55.7 percent male, 82.4 percent ethnic minority, mean age=37.4 years) rated HIV vaccine acceptability from 28.4 to 88.6; mean=54.5 (SD=18.8; 100‐point scale). Efficacy had the greatest impact on acceptability, followed by side effects and out‐of‐pocket cost. Ten percent would decrease condom use after vaccination. Conclusions. Findings support development of social marketing interventions to increase acceptability of “partial efficacy” vaccines, behavioral interventions to mitigate risk compensation, and targeted cost subsidies.